{"id":"W4295828450","doi":"10.1016/j.annonc.2022.07.1262","title":"1138P Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 >/= 50%: 3 weekly compared to 6 weekly dosing","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Dosing; Medicine; Pembrolizumab; Internal medicine; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008896315,0.000443315,0.001869297,0.0003185345,0.0002982137,0.0009765904,0.0006268779,0.001111918,0.007774258],"category_scores_gemma":[0.001194591,0.000275016,0.0009390769,0.0003242556,0.0004279573,0.001181448,0.0003038792,0.002463094,0.001009009],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006668383,"about_ca_system_score_gemma":0.0007679321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001150229,"about_ca_topic_score_gemma":0.001742961,"domain_scores_codex":[0.9995167,0.0001514859,0.00003574567,0.00009870996,0.00006325611,0.0001340711],"domain_scores_gemma":[0.9996037,0.0001153617,0.00005974697,0.00004034613,0.0000225078,0.0001583885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7963046,0.01171194,0.001684096,0.0002549319,0.0004724156,0.0000766807,0.000101912,0.001789496,0.02073906,0.0003413815,0.002192806,0.1643306],"study_design_scores_gemma":[0.3486901,0.5661362,0.04649126,0.0001757715,0.001837235,0.0003949745,0.0002339921,0.01105821,0.014332,0.001246291,0.009258234,0.000145828],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943731,0.001941404,0.0004924322,0.0003272017,0.0003820967,0.0002345192,0.0003246151,0.00009267036,0.001832068],"genre_scores_gemma":[0.9966762,0.0004879709,0.000867175,0.0001909865,0.0001138692,0.0002378666,0.0002241202,0.00002126332,0.001180648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007774258,"threshold_uncertainty_score":0.02600747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05550377184018356,"score_gpt":0.3689217941211834,"score_spread":0.3134180222809998,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}